吉西他滨联合厄洛替尼治疗晚期胰腺癌的观察
顾艳宏， 束永前， 黄普文， 朱蔚友， 朱程君， 李薇 - 临床肿瘤学杂志, 2006 - cqvip.com
目的: 观察吉西他滨(健择) 联合厄洛替尼(erlotinib, Tarceva) 治疗晚期胰腺癌的疗效,
临床受益反应和毒性反应. 方法: 12 例晚期胰腺癌患者, 均有组织病理学或细胞学诊断及可评价 …
临床受益反应和毒性反应. 方法: 12 例晚期胰腺癌患者, 均有组织病理学或细胞学诊断及可评价 …
Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines
X Xiong, H Liu, L Fu, L Li, J Li, X Luo, C Mei - Chemotherapy, 2008 - karger.com
Epidermal growth factor receptor (EGFR) is one of the important protein tyrosine kinases
(PTKs), whose blockade by tyrosine kinase inhibitors (TKIs) has been introduced in the …
(PTKs), whose blockade by tyrosine kinase inhibitors (TKIs) has been introduced in the …
Nuclear receptors in pancreatic tumor cells
C Damaskos, T Karatzas, ID Kostakis… - Anticancer …, 2014 - ar.iiarjournals.org
Aim: This review focuses on nuclear receptors expressed in pancreatic cancer. Materials
and Methods: An extensive search of articles published up to March 2013 was conducted …
and Methods: An extensive search of articles published up to March 2013 was conducted …
非小细胞肺癌患者的新选择—厄洛替尼(特罗凯)
方振威， 翟所迪 - 中国药物应用与监测, 2008 - cqvip.com
目的: 综述了厄洛替尼的靶向作用, 药动学, 临床研究及不良反应皮疹与疗效的关系. 方法:
通过查阅国内外文献总结了厄洛替尼的单药试验及合并用药试验, 并对研究结果进行分析. 结果 …
通过查阅国内外文献总结了厄洛替尼的单药试验及合并用药试验, 并对研究结果进行分析. 结果 …
[HTML][HTML] In silico evaluation of binding interaction and ADME study of new 1, 3-diazetidin-2-one derivatives with high antiproliferative activity
FH Abdulredha, MF Mahdi, AK Khan - Journal of Advanced …, 2023 - journals.lww.com
A series of eight novels'1, 3-diazetidin-2-ones have been proposed to assess their potential
activities. They are intended to examine antiproliferative effects through inhibition of …
activities. They are intended to examine antiproliferative effects through inhibition of …
Erlotinib-responsive actinic keratoses
JF Hermanns, GE Piérard… - Oncology …, 2007 - spandidos-publications.com
Erlotinib is an inhibitor of the tyrosine-kinase domain of the epidermal growth factor receptor-
1 (EGFR). This drug is used to treat some solid cancers, particularly advanced non-small …
1 (EGFR). This drug is used to treat some solid cancers, particularly advanced non-small …
EGFR-targeting monoclonal antibodies in head and neck cancer
I Astsaturov, RB Cohen, P Harari - Current Cancer Drug …, 2007 - ingentaconnect.com
The epidermal growth factor (EGFR) and its receptor were discovered nearly 40 years ago.
Over the past decade interruption of this pathway has been exploited in the treatment of …
Over the past decade interruption of this pathway has been exploited in the treatment of …
Petri net siphon analysis and graph theoretic measures for identifying combination therapies in cancer
Epidermal Growth Factor Receptor (EGFR) signaling to the Ras-MAPK pathway is
implicated in the development and progression of cancer and is a major focus of targeted …
implicated in the development and progression of cancer and is a major focus of targeted …
Prevention of breast cancer: current state of the science and future opportunities
IP Uray, PH Brown - Expert opinion on investigational drugs, 2006 - Taylor & Francis
Despite significant progress in breast cancer treatment, mammary tumours still represent the
second most frequent cause of cancer-related death in women in the US, with> 211,000 new …
second most frequent cause of cancer-related death in women in the US, with> 211,000 new …